Our report – the My Life With Food Allergy: Parent Survey Report – gives a summary of the emotional, social and financial impact on the parent or caregiver of a child with food allergies. Read more about the findings.
Illinois Governor J.B. Pritzker signed a law on Aug. 9, 2019, that would require health insurance policies in his state to cover epinephrine injectors for children 18 and younger. House Bill 3435 will be effective on Jan. 1, 2020.
Join Anna Luther of My Life and Kids Blog and Kenny Mendez, president and CEO of the Asthma and Allergy Foundation of America (AAFA) and Kids With Food Allergies (KFA), a division of AAFA, for a Facebook Live discussion on new research and insights on the social and emotional impact of food allergies on parents. Also get useful back-to-school advice for parents of kids with food allergies!
Windgap Medical, Inc. announced today that it has a strategic partnership with ALK-Abelló, A/S ("ALK") to commercialize the company's epinephrine autoinjector (EAI) for the treatment of anaphylactic shock.
DBV Technologies, a clinical-stage biopharmaceutical company, today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin® Peanut for the treatment of peanut-allergic children ages 4 to 11 years.
Recently, the FDA has been asking for more data to support adding sesame to the list of top food allergens. A new study titled “Prevalence and Severity of Sesame Allergy in the United States” has been released by the JAMA Network today in response to the FDA’s request.
While experimental desensitization strategies are available in research settings, people with food allergies must avoid known allergens and are advised to carry injectable epinephrine to prevent potentially life-threatening allergic reactions caused by accidental exposures. To help alleviate this risk, a new study to evaluate an experimental treatment for food allergy launched today.
Governor Newsom has signed the Natalie Giorgi Sunshine Act. This bill was authored by Assemblymember Rebecca Bauer-Kahan (AD16 D-Orinda) and named in honor of Natalie Giorgi. Natalie passed away at age 13 due to a severe allergic reaction to undeclared peanut in a treat while at a summer camp in Sacramento. AB 1532 requires all food handlers to have a simple certification in safe food handling practices for major food allergens. This bill also would add “Organized Camps” to the definition of...
On July 25, 2019, Kenny Mendez, President and CEO of the Asthma and Allergy Foundation of America (AAFA), co-hosted a Facebook Live session with pediatrician and blogger, Dr. Katie Freidman of Forever Freckled. If you didn’t have a chance to tune in live, you can still watch the session.
Join Dr. Katie Freidman of Forever Freckled and Kenny Mendez, President and CEO of the Asthma and Allergy Foundation of America (AAFA) and Kids With Food Allergies, a division of AAFA, for a Facebook Live discussion around what parents need to know about new treatments for kids with food allergies, in particular, peanut allergy. Thursday, July 25, 2019, at 1:30 – 2 pm ET.
The Asthma and Allergy Foundation of America (AAFA) addresses concerns regarding the Final Evidence Report assessing the clinical effectiveness and value of treatments for peanut allergy released by the Institute for Clinical and Economic Review (ICER) on July 10, 2019. ICER’s report may cause concern for the allergy community that the findings will restrict access to new treatments for peanut allergy.
Walgreens and kaléo, a privately-held pharmaceutical company, today announced AUVI-q® (epinephrine injection, USP) 0.1 mg auto-injector is available at Walgreens locations nationwide. AUVI-q 0.1 mg is the first and only epinephrine auto-injector (EAI) approved by the U.S. Food and Drug Administration (FDA) for infants and toddlers weighing 16.5 to 33 pounds (7.5 to 15 kilograms). Through this collaboration, Walgreens is the first national retail pharmacy to offer the entire AUVI-Q auto-injector
Sandoz Inc. (Sandoz), a Novartis division, today announced the US retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and pediatric doses immediately available in local pharmacies across the nation.
Connecticut and Texas have passed epinephrine stocking laws for public places. These laws allow places to store and use undesignated epinephrine in case of an allergic emergency.
On June 11, 2019, in Oakland, California, the Institute for Clinical and Economic Review (ICER) and its California Technology Assessment Forum (CTAF) met to assess the clinical effectiveness and value of treatments for peanut allergy. The review examined two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT).